Executive Summary: Europe Prostate Cancer Market

Market Scope: Comprehensive European prostate cancer market analysis covering diagnostic techniques, surgical procedures, radiation therapy classes, chemotherapy options, country-level frameworks, and clinical/treatment adoption drivers.
Market Valuation: Valued at USD 23.64 billion (2025), estimated at USD 25.79 billion (2026), and projected to reach USD 51.77 billion by 2034, registering a robust CAGR of 9.1% (2026–2034).
Primary Growth Drivers: Growing geriatric male population, rising incidence and prevalence of prostate cancer, expanding public awareness, increased R&D investments by drug innovators, and the strong adoption of innovative technologies in screening (such as multiparametric MRI). Key market constraints include high expenses associated with advanced treatments and tissue biopsies, long treatment durations, side effects, and poor reimbursement policies.

Key Market Segment Metrics (2026–2034)

Category	Leading Segment (2025 Position)	Fastest-Growing Segment
By Diagnostic Techniques	Prostate-Specific Antigen (PSA) test (led primary diagnostic screening and detection workflows)	Advanced imaging and multiparametric MRI diagnostic screening modalities
By Surgery	Radical Prostatectomy (accounted for the highest volume among surgical interventions)	Minimally invasive and robot-assisted surgical techniques
By Radiation Therapy	External Beam Radiation Therapy (dominated therapeutic radiation procedures)	Intensity Modulated Radiation Therapy (IMRT) and stereotactic body radiation therapy
By Chemotherapy	Docetaxel (led chemotherapeutic regimens for advanced castrate-resistant stages)	Advanced taxane-based and targeted combination chemotherapies
By Country	Germany (held the leading market share in the European regional landscape)	United Kingdom (forecasted to register a healthy, rapid CAGR across the EU market)

Major Market Players & Market Structure

Market Structure: Highly competitive pharmaceutical and medical device landscape featuring major multinational leaders and specialized therapeutic innovators competing intensely on mCRPC drugs, hormonal therapies, targeted radiation systems, and robust generic product portfolios following patent expirations.

Key Companies: Sanofi S.A., GlaxoSmithKline, AstraZeneca, AbbVie, Varian Medical Systems, Elekta, Theragenics, Pfizer, Novartis, Roche, Bayer, Johnson & Johnson, Abbott Laboratories, and Genentech.

Europe Prostate Cancer Market Size

The Europe prostate cancer market size was valued at USD 23.64 billion in 2025 and is anticipated to reach USD 25.79 billion in 2026 from USD 51.77 billion by 2034, growing at a CAGR of 9.1% during the forecast period from 2026 to 2034.

Prostate cancer is a commercially profitable indication with a high incidence of diagnosis incidences. As a result, the drug treatment of prostate cancer has evolved quickly over the last few years, with the metastatic castrate-resistant prostate cancer (mCRPC) situation becoming more crowded and competitive.

The growth of the European prostate cancer market is majorly driven by the growing geriatric population, an increase in the prevalence of prostate cancer, a surge in generic products, an increase in public awareness about prostate cancer treatment, increased R&D investment by drug innovators, potent emerging pipeline drugs, and the availability of new prostate cancer treatments. Other factors that contribute to the market's growth include an increase in demand for prostate cancer therapy and management and an increase in the use of hormonal treatments in non-metastatic castration-resistant and metastatic hormone naive (mHNPC) prostate cancer settings. This increase is attributed to an aging population, increased smoking, obesity, poor dietary habits, rising prostate cancer prevalence, increased uptake of hormonal agents in non-metastatic castration-resistant and metastatic hormone naive prostate cancer settings, pipeline drugs, and increased demand for prostate cancer treatment and management.

The growing male aging population is driving prostate cancer medications. In males over the age of 60, prostate cancer is one of the most frequent cancers. Growth is expected to be fueled by the adoption of innovative technologies in screening and diagnostic testing. For example, multiparametric MRI can dramatically increase tumor identification while also verifying whether tissue biopsy is required. Furthermore, manufacturers in the market are spending research to create treatments for the treatment of such tumors. Again, due to the expiration of patents on major existing products throughout the projected period, many generic products are likely to enter the market. As a result, growth is expected to be fueled by these factors.

Europe's Prostate Cancer market's growth is likely to be hampered by long treatment times and low demand for prostate cancer treatment medications in this nation. In addition, the market's growth would be impeded by treatment side effects, high expenses. The high costs of a tissue biopsy, especially during the advanced stages of a tumor, and medical consultation fees are projected to limit growth. Furthermore, issues such as poor reimbursement of treatment expenses may have a detrimental impact on the adoption rate of treatment procedures.

REGIONAL ANALYSIS

The European Commission has approved the use of apalutamide in adult males with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy. The European Commission approved the drug based on the phase III TITAN research findings, which looked at the effects of adding apalutamide to ADT in a broad spectrum of patients. Furthermore, due to the expiration of patents on major existing products throughout the forecast period, many generic products are likely to enter the market. As a result, growth is expected to be fuelled by these reasons. Furthermore, many generic products are predicted to enter the market when patents on essential incumbent products expire over the forecast period.

During the forecast period, the UK prostate cancer market is forecasted to register a healthy CAGR in the EU market. However, in 2020, the German prostate cancer market held the leading share in the EU market and is estimated to grow at a promising CAGR during the forecast period.

KEY MARKET PLAYERS

A few noteworthy companies operating in the European prostate cancer market include

Sanofi S.A.
GlaxoSmithKline
AstraZeneca
AbbVie
Varian Medical Systems
Elekta
Theragenics
Pfizer
Novartis
Roche
Bayer
Johnson & Johnson
Abbott Laboratories
Genentech

MARKET SEGMENTATION

This research report on the European Prostate Cancer Market has been segmented and sub-segmented into the following categories.

By Diagnostic Techniques

Digital Rectal Exam (DRE)
Prostate-Specific Antigen Test (PSA)

By Surgery

Radical Prostatectomy
Orchidectomy
Trans Urethral Resection (TUR)

By Radiation Therapy

External Beam Radiation Therapy
- 3D Conformal Radiation Therapy
- Intensity Modulated Radiation Therapy
- Stereotactic Body Radiation Therapy
- Proton Beam Radiation Therapy
Brachytherapy
- Permanent Brachytherapy
- Temporary Brachytherapy

By Chemotherapy

Docetaxel
Etoposide
Vinblastine
Carboplatin
Vinorelbine

By Country

UK
France
Spain
Germany
Italy
Russia
Sweden
Denmark
Switzerland
Netherlands
Turkey
Czech Republic
Rest of Europe

Trusted by 500+ companies. We respect your privacy and never share your data.

Please wait. . . . Your request is being processed

Europe Prostate Cancer Market Report